Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry

Raposeiras-Roubín, Sergio; Núñez-Gil, Iván J; Jamhour, Karim; Abu-Assi, Emad; Conty, David Aritza; Vedia, Oscar; Almendro-Delia, Manuel; Sionis, Alessandro; Martin-Garcia, Agustin C; Corbí-Pascual, Miguel; Martínez-Sellés, Manuel; Uribarri, Aitor; Guillén, Marta; Acuña, José María García; País, Javier Lopez; Blanco, Emilia; Linares Vicente, José A; Flecha, Alejandro Sánchez Grande; Andrés, Mireia; Pérez-Castellanos, Alberto; Alonso, Joaquín; Rosselló, Xavier; Romo, Andrés Iñiguez; Feltes, Gisela

Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry

Background: No evidence-based therapy has yet been established for Takotsubo syndrome (TTS). Given the putative harmful effects of catecholamines in patients with TTS, beta-blockers may potentially decrease the intensity of the detrimental cardiac effects in those patients. Objective: The purpose of...

Descripción completa

Detalles Bibliográficos
Autores:	Raposeiras-Roubín, Sergio, Núñez-Gil, Iván J, Jamhour, Karim, Abu-Assi, Emad, Conty, David Aritza, Vedia, Oscar, Almendro-Delia, Manuel, Sionis, Alessandro, Martin-Garcia, Agustin C, Corbí-Pascual, Miguel, Martínez-Sellés, Manuel, Uribarri, Aitor, Guillén, Marta, Acuña, José María García, País, Javier Lopez, Blanco, Emilia, Linares Vicente, José A, Flecha, Alejandro Sánchez Grande, Andrés, Mireia, Pérez-Castellanos, Alberto, Alonso, Joaquín, Rosselló, Xavier, Romo, Andrés Iñiguez, Feltes, Gisela
Tipo de recurso:	artículo
Fecha de publicación:	2023
País:	España
Institución:	Instituto de Salud Carlos III (ISCIII)
Repositorio:	Repisalud
Idioma:	inglés
OAI Identifier:	oai:repisalud.isciii.es:20.500.12105/16451
Acceso en línea:	http://hdl.handle.net/20.500.12105/16451
Access Level:	acceso abierto
Palabra clave:	Estudios de Cohortes Humanos Cardiomiopatía de Takotsubo Pronóstico Cuidados Posteriores Alta del Paciente Sistema de Registros Takotsubo Cardiomyopathy Humans Aftercare Cohort Studies Patient Discharge Prognosis Registries

id	ES_e47c55ed4be5beabbe07e73bb5e434b2
oai_identifier_str	oai:repisalud.isciii.es:20.500.12105/16451
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO RegistryRaposeiras-Roubín, SergioNúñez-Gil, Iván JJamhour, KarimAbu-Assi, EmadConty, David AritzaVedia, OscarAlmendro-Delia, ManuelSionis, AlessandroMartin-Garcia, Agustin CCorbí-Pascual, MiguelMartínez-Sellés, ManuelUribarri, AitorGuillén, MartaAcuña, José María GarcíaPaís, Javier LopezBlanco, EmiliaLinares Vicente, José AFlecha, Alejandro Sánchez GrandeAndrés, MireiaPérez-Castellanos, AlbertoAlonso, JoaquínRosselló, XavierRomo, Andrés IñiguezFeltes, GiselaEstudios de CohortesHumanosCardiomiopatía de TakotsuboPronósticoCuidados PosterioresAlta del PacienteSistema de RegistrosTakotsubo CardiomyopathyHumansAftercareCohort StudiesPatient DischargePrognosisRegistriesBackground: No evidence-based therapy has yet been established for Takotsubo syndrome (TTS). Given the putative harmful effects of catecholamines in patients with TTS, beta-blockers may potentially decrease the intensity of the detrimental cardiac effects in those patients. Objective: The purpose of this study was to assess the impact of beta-blocker therapy on long-term mortality and TTS recurrence. Methods: The cohort study used the national Spanish Registry on TakoTsubo Syndrome (RETAKO). A total of 970 TTS post-discharge survivors, without pheochromocytoma, left ventricular outflow tract obstruction, sustained ventricular arrhythmias, and significant bradyarrhythmias, between January 1, 2003, and July 31, 2018, were assessed. Cox regression analysis and inverse probability weighting (IPW) propensity score analysis were used to evaluate the association between beta-blocker therapy and survival free of TTS recurrence. Results: From 970 TTS patients, 582 (60.0%) received beta-blockers. During a mean follow-up of 2.5±3.3 years, there were 87 deaths (3.6 per 100 patients/year) and 29 TTS recurrences (1.2 per 100 patient/year). There was no significant difference in follow-up mortality or TTS recurrence in unadjusted and adjusted Cox analysis (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.59-1.27, and 0.95, 95% CI 0.57-1.13, respectively). After weighting and adjusting by IPW, differences in one-year survival free of TTS recurrence between patients treated and untreated with beta-blockers were not found (average treatment effect -0.01, 95% CI -0.07 to 0.04; p=0.621). Conclusions: In this observational nationwide study from Spain, there was no significant association between beta-blocker therapy and follow-up survival free of TTS recurrence.Elsevier20232023-09-1220232023-03-0120232023-03-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/16451reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/164512026-06-12T12:43:37Z
dc.title.none.fl_str_mv	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
title	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
spellingShingle	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry Raposeiras-Roubín, Sergio Estudios de Cohortes Humanos Cardiomiopatía de Takotsubo Pronóstico Cuidados Posteriores Alta del Paciente Sistema de Registros Takotsubo Cardiomyopathy Humans Aftercare Cohort Studies Patient Discharge Prognosis Registries
title_short	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
title_full	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
title_fullStr	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
title_full_unstemmed	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
title_sort	Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
dc.creator.none.fl_str_mv	Raposeiras-Roubín, Sergio Núñez-Gil, Iván J Jamhour, Karim Abu-Assi, Emad Conty, David Aritza Vedia, Oscar Almendro-Delia, Manuel Sionis, Alessandro Martin-Garcia, Agustin C Corbí-Pascual, Miguel Martínez-Sellés, Manuel Uribarri, Aitor Guillén, Marta Acuña, José María García País, Javier Lopez Blanco, Emilia Linares Vicente, José A Flecha, Alejandro Sánchez Grande Andrés, Mireia Pérez-Castellanos, Alberto Alonso, Joaquín Rosselló, Xavier Romo, Andrés Iñiguez Feltes, Gisela
author	Raposeiras-Roubín, Sergio
author_facet	Raposeiras-Roubín, Sergio Núñez-Gil, Iván J Jamhour, Karim Abu-Assi, Emad Conty, David Aritza Vedia, Oscar Almendro-Delia, Manuel Sionis, Alessandro Martin-Garcia, Agustin C Corbí-Pascual, Miguel Martínez-Sellés, Manuel Uribarri, Aitor Guillén, Marta Acuña, José María García País, Javier Lopez Blanco, Emilia Linares Vicente, José A Flecha, Alejandro Sánchez Grande Andrés, Mireia Pérez-Castellanos, Alberto Alonso, Joaquín Rosselló, Xavier Romo, Andrés Iñiguez Feltes, Gisela
author_role	author
author2	Núñez-Gil, Iván J Jamhour, Karim Abu-Assi, Emad Conty, David Aritza Vedia, Oscar Almendro-Delia, Manuel Sionis, Alessandro Martin-Garcia, Agustin C Corbí-Pascual, Miguel Martínez-Sellés, Manuel Uribarri, Aitor Guillén, Marta Acuña, José María García País, Javier Lopez Blanco, Emilia Linares Vicente, José A Flecha, Alejandro Sánchez Grande Andrés, Mireia Pérez-Castellanos, Alberto Alonso, Joaquín Rosselló, Xavier Romo, Andrés Iñiguez Feltes, Gisela
author2_role	author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv	Estudios de Cohortes Humanos Cardiomiopatía de Takotsubo Pronóstico Cuidados Posteriores Alta del Paciente Sistema de Registros Takotsubo Cardiomyopathy Humans Aftercare Cohort Studies Patient Discharge Prognosis Registries
topic	Estudios de Cohortes Humanos Cardiomiopatía de Takotsubo Pronóstico Cuidados Posteriores Alta del Paciente Sistema de Registros Takotsubo Cardiomyopathy Humans Aftercare Cohort Studies Patient Discharge Prognosis Registries
description	Background: No evidence-based therapy has yet been established for Takotsubo syndrome (TTS). Given the putative harmful effects of catecholamines in patients with TTS, beta-blockers may potentially decrease the intensity of the detrimental cardiac effects in those patients. Objective: The purpose of this study was to assess the impact of beta-blocker therapy on long-term mortality and TTS recurrence. Methods: The cohort study used the national Spanish Registry on TakoTsubo Syndrome (RETAKO). A total of 970 TTS post-discharge survivors, without pheochromocytoma, left ventricular outflow tract obstruction, sustained ventricular arrhythmias, and significant bradyarrhythmias, between January 1, 2003, and July 31, 2018, were assessed. Cox regression analysis and inverse probability weighting (IPW) propensity score analysis were used to evaluate the association between beta-blocker therapy and survival free of TTS recurrence. Results: From 970 TTS patients, 582 (60.0%) received beta-blockers. During a mean follow-up of 2.5±3.3 years, there were 87 deaths (3.6 per 100 patients/year) and 29 TTS recurrences (1.2 per 100 patient/year). There was no significant difference in follow-up mortality or TTS recurrence in unadjusted and adjusted Cox analysis (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.59-1.27, and 0.95, 95% CI 0.57-1.13, respectively). After weighting and adjusting by IPW, differences in one-year survival free of TTS recurrence between patients treated and untreated with beta-blockers were not found (average treatment effect -0.01, 95% CI -0.07 to 0.04; p=0.621). Conclusions: In this observational nationwide study from Spain, there was no significant association between beta-blocker therapy and follow-up survival free of TTS recurrence.
publishDate	2023
dc.date.none.fl_str_mv	2023 2023-09-12 2023 2023-03-01 2023 2023-03-01
dc.type.none.fl_str_mv	research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	http://hdl.handle.net/20.500.12105/16451
url	http://hdl.handle.net/20.500.12105/16451
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII)
instname_str	Instituto de Salud Carlos III (ISCIII)
reponame_str	Repisalud
collection	Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869422595279945728
score	15,812429

Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry

Similares en LA Referencia